Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: A differential risk assessment and decision model for Transarterial chemoembolization in hepatocellular carcinoma based on hepatic function

Fig. 1

Consort diagram. A total of 763 HCC patients who received TACE as initial treatment for unresectable HCC were enrolled from two large-volume university hospitals. Of these, 166 patients were excluded and 597 patients were enrolled for analysis. A total of 739 HCC patients from independent university hospital were enrolled to validate the model externally

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us